Nach Absetzen von Tirzepatid steigt das kardiometabolische Risiko

CME 2026

View at publisher
Authors: Beate Schumacher
DOI: 10.1007/s11298-025-4485-z
Cited by: 0

Fields of Study & Subjects

Diabetes Treatment and Management Pharmacology and Obesity Treatment Diabetes Cardiovascular Risks and Lipoproteins

Publication details

Journal / source
CME
Volume
23
Issue
1-2
Pages
38–39
Publication date
1 February 2026
Language
DE